论文部分内容阅读
目的:观察阿托伐他汀短期干预对血脂异常兔血清及脂肪组织分泌脂肪细胞型脂肪酸结合蛋白(AFABP)的影响,并阐明其可能机制。方法:15只新西兰大白兔随机均分为3组:①对照组,给予普通饮食12周;②高胆固醇组,给予高胆固醇饲料12周;③阿托伐他汀组,在饲以高胆固醇饲料8周的基础上给予阿托伐他汀1.5mg·kg-1.d-14周。应用RT-PCR技术测定脂肪组织AFABP mRNA的表达;ELISA法检测血清及脂肪组织培养液中AFABP水平。结果:实验第8周、第12周时高胆固醇组血清总胆固醇、低密度脂蛋白胆固醇水平明显高于对照组(P<0.01);阿托伐他汀组经阿托伐他汀干预后对血脂产生明显影响,并能降低血清及脂肪组织上清液AFABP水平,与高胆固醇组比较,均P<0.05。阿托伐他汀降低血清AFABP水平与降低脂肪组织上清液AFABP水平呈正相关(r=0.943,P<0.05)。RT-PCR结果显示,高胆固醇组脂肪组织AFABP mRNA表达高于对照组(P<0.05);阿托伐他汀组较高胆固醇组能降低兔脂肪组织AFABP mRNA的表达(P<0.05)。结论:阿托伐他汀能降低血脂异常兔血清及脂肪组织上清液AFABP水平,这可能是阿托伐他汀抗动脉粥样硬化的多效性机制之一。
Objective: To observe the effect of atorvastatin on the expression of adipocyte-type fatty acid-binding protein (AFABP) in serum and adipose tissue of rabbits with dyslipidemia and to clarify its possible mechanism. Methods: Fifteen New Zealand white rabbits were randomly divided into three groups: ① control group, given a normal diet for 12 weeks; ② high cholesterol group, given high cholesterol diet for 12 weeks; ③ atorvastatin group, fed with high cholesterol diet 8 Atorvastatin 1.5 mg · kg-1.d-14 weeks was given on a weekly basis. The expression of AFABP mRNA in adipose tissue was detected by RT-PCR. The level of AFABP in serum and adipose tissue was detected by ELISA. Results: At the 12th week and the 12th week, the level of serum total cholesterol and low density lipoprotein cholesterol in the hypercholesterolemia group were significantly higher than those in the control group (P <0.01). Atorvastatin group Obviously, and can reduce the serum and adipose tissue supernatant AFABP levels, compared with the high cholesterol group, P <0.05. Atorvastatin reduced serum AFABP levels and decreased adipose tissue supernatant AFABP level was positively correlated (r = 0.943, P <0.05). The results of RT-PCR showed that the expression of AFABP mRNA in adipose tissue of hypercholesterolemic group was higher than that of control group (P <0.05). The high cholesterol group of atorvastatin group could reduce the expression of AFABP mRNA (P <0.05). Conclusion: Atorvastatin can reduce the level of AFABP in serum and adipose tissue supernatant of dyslipidemia, which may be one of the pleiotropic mechanisms of atorvastatin against atherosclerosis.